Literature DB >> 20730619

Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction.

Christos Kalofoutis1, Iordanis Mourouzis, Georgios Galanopoulos, Antonios Dimopoulos, Philippos Perimenis, Danai Spanou, Dennis V Cokkinos, Jaipaul Singh, Constantinos Pantos.   

Abstract

It has been previously shown that regulators of physiological growth such as thyroid hormone (TH) can favorably remodel the post ischaemic myocardium. Here, we further explored whether this effect can be preserved in the presence of co-morbidities such as diabetes which accelerates cardiac remodeling and increases mortality after myocardial infarction. Acute myocardial infarction (AMI) was induced by left coronary ligation in rats with type I diabetes (DM) induced by streptozotocin administration (STZ; 35 mg/kg; i.p.) while sham-operated animals served as controls (SHAM). AMI resulted in distinct changes in cardiac function and geometry; EF% was significantly decreased in DM-AMI [37.9 ± 2.0 vs. 74.5 ± 2.1 in DM-SHAM]. Systolic and diastolic chamber dimensions were increased without concomitant increase in wall thickness and thus, wall tension index [WTI, the ratio of (Left Ventricular Internal Diameter at diastole)/2*(Posterior Wall thickness)], an index of wall stress, was found to be significantly increased in DM-AMI; 2.27 ± 0.08 versus 1.70 ± 0.05. 2D-Strain echocardiographic analysis showed reduced systolic radial strain in all segments, indicating increased loss of cardiac myocytes in the infarct related area and less compensatory hypertrophy in the viable segments. This response was accompanied by a marked decrease in the expression of TRα1 and TRβ1 receptors in the diabetic myocardium without changes in circulating T3 and T4. Accordingly, the expression of TH target genes related to cardiac contractility was altered; β-MHC and PKCα were significantly increased. TH (L-T4 and L-T3) administration prevented these changes and resulted in increased EF%, normal wall stress and increased systolic radial strain in all myocardial segments. Acute myocardial infarction in diabetic rats results in TH receptor down-regulation with important physiological consequences. TH treatment prevents this response and improves cardiac hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20730619     DOI: 10.1007/s11010-010-0569-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  37 in total

1.  Thyroid hormone receptors alpha1 and beta1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion.

Authors:  C Pantos; I Mourouzis; T Saranteas; I Paizis; C Xinaris; V Malliopoulou; D V Cokkinos
Journal:  Basic Res Cardiol       Date:  2005-09       Impact factor: 17.165

2.  Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase.

Authors:  Koichiro Kinugawa; Mark Y Jeong; Michael R Bristow; Carlin S Long
Journal:  Mol Endocrinol       Date:  2005-04-14

3.  Thyroid hormone represses protein kinase C isoform expression and activity in rat cardiac myocytes.

Authors:  V Rybin; S F Steinberg
Journal:  Circ Res       Date:  1996-09       Impact factor: 17.367

4.  Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Konstantinos Markakis; Nikolaos Tsagoulis; Matthew Panagiotou; Dennis V Cokkinos
Journal:  Basic Res Cardiol       Date:  2008-02-15       Impact factor: 17.165

5.  Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"?

Authors:  C Pantos; C Xinaris; I Mourouzis; P Perimenis; E Politi; D Spanou; D V Cokkinos
Journal:  J Physiol Pharmacol       Date:  2008-06       Impact factor: 3.011

6.  Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Konstantinos Markakis; Antonios Dimopoulos; Christodoulos Xinaris; Alexandros D Kokkinos; Matthew Panagiotou; Dennis V Cokkinos
Journal:  Eur J Cardiothorac Surg       Date:  2007-06-07       Impact factor: 4.191

7.  Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats.

Authors:  Hesham Soliman; Graham P Craig; Prabhakar Nagareddy; Violet G Yuen; Guorong Lin; Ujendra Kumar; John H McNeill; Kathleen M Macleod
Journal:  Cardiovasc Res       Date:  2008-04-14       Impact factor: 10.787

Review 8.  Protection of the abnormal heart.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

9.  Early blood pressure-independent cardiac changes in diabetic rats.

Authors:  Daniel Landau; Chen Chayat; Nili Zucker; Eli Golomb; Channa Yagil; Yoram Yagil; Yael Segev
Journal:  J Endocrinol       Date:  2008-04       Impact factor: 4.286

Review 10.  Rebuilding the post-infarcted myocardium by activating 'physiologic' hypertrophic signaling pathways: the thyroid hormone paradigm.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2008-09-05       Impact factor: 4.214

View more
  12 in total

1.  Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings.

Authors:  Iordanis Mourouzis; Polixeni Mantzouratou; Georgios Galanopoulos; Erietta Kostakou; Nikolaos Roukounakis; Alexandros D Kokkinos; Dennis V Cokkinos; Constantinos Pantos
Journal:  Mol Cell Biochem       Date:  2011-12-02       Impact factor: 3.396

Review 2.  Role of thyroid hormones in ventricular remodeling.

Authors:  Viswanathan Rajagopalan; A Martin Gerdes
Journal:  Curr Heart Fail Rep       Date:  2015-04

Review 3.  Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor α1 in cardiac repair.

Authors:  Constantinos Pantos; Iordanis Mourouzis
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

4.  Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes.

Authors:  Valentina Benedetti; Angelo Michele Lavecchia; Monica Locatelli; Valerio Brizi; Daniela Corna; Marta Todeschini; Rubina Novelli; Ariela Benigni; Carlamaria Zoja; Giuseppe Remuzzi; Christodoulos Xinaris
Journal:  JCI Insight       Date:  2019-09-19

Review 5.  Thyroid hormones and cardiac remodeling.

Authors:  Dennis V Cokkinos; Stavros Chryssanthopoulos
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

6.  Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice.

Authors:  Iordanis Mourouzis; Erietta Kostakou; Georgios Galanopoulos; Polixeni Mantzouratou; Constantinos Pantos
Journal:  Mol Cell Biochem       Date:  2013-03-27       Impact factor: 3.396

7.  Regulation of gene expression with thyroid hormone in rats with myocardial infarction.

Authors:  Yue-Feng Chen; James V Pottala; Nathan Y Weltman; Xijin Ge; Olga V Savinova; A Martin Gerdes
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

8.  Thyroid hormone and cardiac disease: from basic concepts to clinical application.

Authors:  Iordanis Mourouzis; Francesca Forini; Constantinos Pantos; Giorgio Iervasi
Journal:  J Thyroid Res       Date:  2011-06-19

Review 9.  The emerging role of TRα1 in cardiac repair: potential therapeutic implications.

Authors:  Constantinos Pantos; Iordanis Mourouzis
Journal:  Oxid Med Cell Longev       Date:  2014-02-09       Impact factor: 6.543

10.  Time‑dependent and independent effects of thyroid hormone administration following myocardial infarction in rats.

Authors:  Ioanna Iliopoulou; Iordanis Mourouzis; George I Lambrou; Dimitra Iliopoulou; Dimitrios-Dionysios Koutsouris; Constantinos Pantos
Journal:  Mol Med Rep       Date:  2018-05-11       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.